ASTRA'S FOSCARNET EXPANDED PHASE II CLINICALS WILL BEGIN IN MARCH
ASTRA'S FOSCARNET EXPANDED PHASE II CLINICALS WILL BEGIN IN MARCH, the company said following a Jan. 30 FDA press release on new studies for experimental AIDS drugs. The new Phase II trial will involve 268 individuals with a second episode of cytomagalovirus, having failed treatment with Syntex' Cytovene (ganciclovir). Phase II trials with foscarnet initially began in September 1988 in three centers. The study included 60 patients with first-episode cytomegalovirus retinitis, an AIDS-related opportunistic infection. In conjunction with the National Institutes for Allergy and Infectious Diseases, Astra is recruiting 180 more patients to expand the trials to six centers. Westboro, Massachussetts-based Astra said it is planning to file for Treatment IND distribution of foscarnet as soon as sufficient data have been collected. Controlled clinical trials of ganciclovir are being conducted under a Treatment IND approved in November. Both foscarnet and ganciclovir are being studied at NIAID's National Eye Institute. A study reported in the Feb. 2 issue of the New England Journal of Medicine suggests that foscarnet may also be useful in the treatment of mucotaneous infections due to acyclovir-resistant herpes simplex virus in AIDS patients. A patient who relapsed after treatments with acyclovir was given foscarnet at a dose of 50 mg per kg three times daily. At the end of 16 days lesions due to the infections disappeared and did not return.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth